Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...
BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...
The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...
The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...
Our roundup of financings in the biotech arena this week is led by a $125 million Series A for Ambros Therapeutics, a startup ...
At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for ...
The UK has reached a critical inflection point in its digital journey. Over $40 billion in fresh commitments from global ...
The ECDC warns of a ‘perfect storm’ and calls for innovation, including through the development of new medicines, enhanced ...
In a new pharmaphorum podcast, guest Patrick Leung – chief technology officer at Faro Health – discusses how AI can transform clinical trials.
According to Reuters, MSD – known as Merck & Co in the US and Canada – is set to be the recipient of the 17th and 18th Commissioner's National Priority Vouchers (CNPVs) for oral PCSK9 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results